双歧杆菌三联活菌辅助治疗乙型肝炎病毒感染失代偿期肝硬化的临床疗效及对患者肝功能的影响

Effect of Bifidobacterium triple viable in adjuvant treatment of hepatitis B virus infection in patients with decompensated cirrhosis and its effect on liver function

目的探讨双歧杆菌三联活菌辅助治疗乙型肝炎病毒(HBV)感染失代偿期肝硬化的临床疗效及对患者肝功能的影响。方法选取2018年4月至2019年4月东莞市人民医院收治的60例HBV感染失代偿期肝硬化患者作为研究对象,按照随机数字表法分为观察组和对照组,每组30例。对照组给予恩替卡韦分散片治疗,观察组在对照组基础上联合双歧杆菌三联活菌治疗,比较两组临床疗效、肝功能和HBV抗病毒相关指标。结果观察组治疗总有效率(93.33%)高于对照组(73.33%),差异有统计学意义(P<0.05)。治疗后,观察组谷草转氨酶(AST)、谷丙转氨酶(ALT)、总胆红素(TBil)水平均明显低于对照组,清蛋白(Alb)水平明显高于对照组,差异有统计学意义(P<0.05)。治疗后,观察组HBV-DNA水平明显低于对照组(P<0.05);观察组HBV-DNA转阴率(96.67%)和HBeAg转阴率(93.33%)均明显高于对照组(73.33%、73.33%),差异有统计学意义(P<0.05)。结论联合双歧杆菌三联活菌辅助治疗HBV感染失代偿期肝硬化效果显著,可显著改善患者肝功能,抑制HBV-DNA的复制,有助于乙肝转阴,值得临床推广应用。

Objective To investigate the effect of Bifidobacterium triple viable in adjuvant treatment of hepatitis B virus(HBV)infection in patients with decompensated cirrhosis and its effect on liver function.Methods 60 patients with decompensated liver cirrhosis due to HBV infection in Dongguan People's Hospital from April 2018 to April 2019 were selected as the research subjects,and they were divided into the observation group and the control group according to random number table method,with 30 cases in each group.The control group was treated with entecavir dispersible tablets,and the observation group was treated with Bifidobacterium triple viable on the basis of the control group,the clinical efficacy,liver function level before and HBV anti-virus related indicators were compared between the two groups.Results The total effective rate of the observation group(93.33%)was significantly higher than(73.33%)of the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of aspartate aminotransferase(AST),alanine aminotransferase(ALT)and serum total bilirubin(TBil)in the observation group were significantly lower than those in the control group,and the level of albumin(Alb)was significantly higher than that in the control group,and the difference was statistically significant(P<0.05).After treatment,the level of HBV-DNA in the observation group was significantly lower than that in the control group(P<0.05);the negative conversion rate of HBV-DNA(96.67%)and the negative rate of HBeAg(93.33%)in the observation group were significantly higher than those in the control group(73.33%,73.33%),the difference was statistically significant(P<0.05).Conclusion Bifidobacterium triple viable in adjuvant treatment of HBV infection in decompensated cirrhosis has good clinical efficacy,can significantly improve the liver function of patients,inhibit the replication of HBV-DNA,and help to turn negative for hepatitis B,which is worthy of clinical application.